Role of SGLT2 Inhibitors in the Nephrology Practice
Target Audience
Learning Objectives
- Have increased knowledge regarding the
- Mechanism of action of SGLT2 inhibitors related to impact on renal outcomes
- Have greater competence related to
- Treating diabetic kidney disease in safe and effective ways
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
MODERATOR
Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas
United States
FACULTY
Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana, United States
Scientia Professor of Medicine
George Institute
UNSW Sydney
Sydney, Australia
STEERING COMMITTEE MEMBER
Professor of Medicine
Director, AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois, United States
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Click here to view the activity or if you are logged in click on the "Complete Activity" button!